Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 NanoString PanCancer Pathways® differentially expressed genes

From: Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

mRNALog2 fold changeStandard error (log2)Linear fold changep valueGene sets
SPP1− 2.960.8040.1290.0017PI3K
CDKN2A− 2.050.8050.2420.0211Cell cycle, apoptosis, tumor suppressor gene
CNTFR− 1.980.7020.2530.0111JAK-STAT
DDIT4− 1.650.5570.3190.0848PI3K
WNT5A− 1.490.7020.3550.0474Hedgehog, Wnt
ITGA91.010.362.020.0116PI3K
LAT1.070.4532.10.0297Ras
IL7R1.080.4272.110.0214JAK-STAT, PI3K
PPARGC1A1.210.5192.320.0312Chromatin modification
TSLP1.230.5442.340.0379JAK-STAT
ID41.310.3532.470.00163TGF-β
TNR1.330.6022.520.0408PI3K
RASGRP21.420.6142.680.0336MAPK, Ras
HNF1A1.490.5912.80.0223Driver gene
COL2A11.590.6063.010.0178PI3K
EFNA21.690.6263.220.0154PI3K, Ras
CCR71.70.683.250.0229Transcriptional misregulation
IL2ORB1.710.6073.260.0116JAK-STAT
WNT161.870.7773.660.0277Hedgehog, transcriptional misregulation, Wnt
CALML52.070.7494.210.0127Ras
IL62.510.7075.710.00244JAK-STAT, PI3K, transcriptional misregulation
CD192.620.7646.130.00323PI3K